An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
about
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisProfile of neratinib and its potential in the treatment of breast cancerCo-Targeting of JNK and HUNK in Resistant HER2-Positive Breast CancerLapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in TumorReceptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathwayAcquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerHeregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceDevelopment of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsPreclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsHeregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.Array-based proteomic approaches to study signal transduction pathways: prospects, merits and challenges.Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.The role of neratinib in HER2-driven breast cancer.Protein network construction using reverse phase protein array data.Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Dual-Color, Multiplex Analysis of Protein Microarrays for Precision Medicine.Signaling pathway profiling using reverse-phase protein array and its clinical applications.Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
P2860
Q21132316-D8E58D1B-ADE0-4AEE-B264-72C1F0A8CBA7Q27012540-45BF6EC6-EF8C-48B0-97EB-72FB8B73470DQ27314840-72CEA019-6594-462E-BDC6-DAADD48C44A2Q27342948-7AA53A71-4BBC-42FE-A8A4-D4AA045571CAQ27853122-6DDD8909-278E-4241-942F-32D437C4C766Q27853182-783144F9-11E2-4554-8E41-2DCBFAB5B0D7Q30278883-46931616-53AA-4B38-8195-382C524C46B4Q30412086-02481DBE-898E-4AD6-B6C7-B5D9A16AE83AQ33709971-4ACC175A-3D78-4F9A-A42E-F13B0CED0BF5Q33850616-239BC120-BAE6-4EFB-B859-801EB19F963AQ35535547-095FDF2E-40A4-4C08-95A8-321A09E9F36EQ35689023-FDA2D5E0-455F-4B51-BC2E-BEB47339F9F3Q35742383-B196AE0D-5AA4-4752-BDE5-8367C1DB48DCQ36117785-D9481282-121A-4007-A5C7-66B3EA8BD55BQ36238664-83D2E5FC-37B2-4B6B-9A0B-F006D1398F30Q36250585-9785EB96-F9AF-4BB4-9E16-E2E54BD092F6Q36311216-833721E0-4AB3-4DD9-AC52-433E803CC6C1Q36387554-F6A2A215-E235-461B-ACB3-739F5ED26CBDQ36455404-D0383819-D1C7-4D6F-A897-5DB2C0C38208Q36771985-3B940126-51D8-4B67-903B-B3281015C162Q37109776-516D7E14-B151-4DAB-8393-18069338E24BQ37698914-8673311E-C62F-440E-A5AF-052F78F2B093Q37709032-779A735F-D731-4290-A802-C41C75506B9CQ38214802-0C5B5DEE-C21D-452B-8590-597A0904165AQ38238616-35EAD715-16D9-4782-BC92-BCA55675E052Q38255299-FA51F950-5AAF-4250-B40A-B15182779995Q38591976-341B59D7-DC46-41E7-967D-92C45BAF1488Q38623361-0B08C51F-3F28-4936-877B-675A00682206Q38664492-9C3F1FC1-053B-42F9-98F8-C3BA3ECB341EQ38708267-2EC43BB0-1FC1-402A-A4EA-B12D8977D344Q38785003-9332EF85-6F8B-4D71-B068-4062E55BBCB0Q38812867-A142F05F-6F10-4EF5-900E-DB04DBEA35E2Q38835146-F052AB3B-AC12-4AD2-BB14-0B709FE1D929Q38861026-1C66E944-B774-4196-AFF6-CDFA32863237Q38966416-14114911-9A38-4BAA-A111-A9F1744DBA88Q39377837-DB1F0078-9CC1-4A0D-80BA-31B485F39E80Q39389369-99F18CD9-C8A8-498E-849F-7BF58C526DD0Q39455125-217FEF9C-1EAF-4DB1-991D-2F9B236170DEQ40176588-90B6EAAA-7AF5-4A10-A593-16C0228A35FDQ41708988-46A211C8-DCD2-4386-92EA-915460738607
P2860
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@en
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@nl
type
label
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@en
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@nl
prefLabel
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@en
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@nl
P2093
P2860
P356
P1476
An heregulin-EGFR-HER3 autocri ...... in HER2+ breast cancer models.
@en
P2093
Emanual F Petricoin
Julia D Wulfkuhle
Leihua Liu
Neil L Spector
Qing Cheng
Rosa I Gallagher
Sarah Bacus
Sumin Zhao
Takuya Osada
P2860
P2888
P356
10.1186/BCR3480
P577
2013-01-01T00:00:00Z
P5875
P6179
1047618553